Anaplastic lymphoma kinase in human cancer
2012 (English)In: Critical reviews in oncogenesis, ISSN 0893-9675, Vol. 17, no 2, 123-143 p.Article in journal (Refereed) Published
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment.
Place, publisher, year, edition, pages
2012. Vol. 17, no 2, 123-143 p.
ALK, NSCLC, neuroblastoma, inhibitors, receptor tyrosine kinases, oncogene
Cell and Molecular Biology
IdentifiersURN: urn:nbn:se:umu:diva-55158PubMedID: 22471704OAI: oai:DiVA.org:umu-55158DiVA: diva2:530215